Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells - PubMed (original) (raw)
. 2002 May 1;62(9):2478-82.
Affiliations
- PMID: 11980636
Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells
Nicola J Mabjeesh et al. Cancer Res. 2002.
Abstract
Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factor composed of alpha and beta subunits. HIF-1 is critically involved in cellular responses to hypoxia, glycolysis, and angiogenesis. Here, we show that treatment of prostate cancer PC-3 and LNCaP cells with the benzoquinone ansamycin geldanamycin, an Hsp90-specific inhibitor, induced degradation of HIF-1alpha protein in a dose- and time-dependent manner under both normoxia and hypoxia. This inhibition was also shown in other common cancer types tested. Rapid degradation of nuclear HIF-1alpha protein levels was accompanied by respective inhibition in HIF-1alpha functional transcription activity of VEGF. No difference between HIF-1alpha mRNA levels before or after geldanamycin treatment was found. Moreover, [35S]methionine pulse-chase analysis revealed that HIF-1alpha protein half-life was markedly decreased in the presence of geldanamycin compared with that in control. The geldanamycin-induced degradation of HIF-1alpha was reversed by proteosome inhibitors lactacystin and MG-132. We conclude that geldanamycin induces reduction of HIF-1alpha levels and its downstream transcriptional activity by accelerating protein degradation independent of O2 tension. Thus, benzoquinone ansamycin drugs and their derivatives, such as 17-allyl-aminogeldanamycin, are excellent candidates as small molecule drug inhibitors of HIF-1 overexpression in cancer cells.
Similar articles
- Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells.
Alqawi O, Moghaddas M, Singh G. Alqawi O, et al. Prostate Cancer Prostatic Dis. 2006;9(2):126-35. doi: 10.1038/sj.pcan.4500852. Epub 2006 Jan 24. Prostate Cancer Prostatic Dis. 2006. PMID: 16432534 - Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors.
Ibrahim NO, Hahn T, Franke C, Stiehl DP, Wirthner R, Wenger RH, Katschinski DM. Ibrahim NO, et al. Cancer Res. 2005 Dec 1;65(23):11094-100. doi: 10.1158/0008-5472.CAN-05-1877. Cancer Res. 2005. PMID: 16322259 - Hypoxia-inducible factor-1 in human breast and prostate cancer.
Kimbro KS, Simons JW. Kimbro KS, et al. Endocr Relat Cancer. 2006 Sep;13(3):739-49. doi: 10.1677/erc.1.00728. Endocr Relat Cancer. 2006. PMID: 16954428 Review. - Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity.
Neckers L, Schulte TW, Mimnaugh E. Neckers L, et al. Invest New Drugs. 1999;17(4):361-73. doi: 10.1023/a:1006382320697. Invest New Drugs. 1999. PMID: 10759403 Review.
Cited by
- Plants and their active compounds: natural molecules to target angiogenesis.
Lu K, Bhat M, Basu S. Lu K, et al. Angiogenesis. 2016 Jul;19(3):287-95. doi: 10.1007/s10456-016-9512-y. Epub 2016 May 6. Angiogenesis. 2016. PMID: 27154020 Free PMC article. Review. - Isolation of hypoxia-inducible factor 1 (HIF-1) inhibitors from frankincense using a molecularly imprinted polymer.
Lakka A, Mylonis I, Bonanou S, Simos G, Tsakalof A. Lakka A, et al. Invest New Drugs. 2011 Oct;29(5):1081-9. doi: 10.1007/s10637-010-9440-4. Epub 2010 May 1. Invest New Drugs. 2011. PMID: 20437079 - Real-time imaging of HIF-1alpha stabilization and degradation.
Moroz E, Carlin S, Dyomina K, Burke S, Thaler HT, Blasberg R, Serganova I. Moroz E, et al. PLoS One. 2009;4(4):e5077. doi: 10.1371/journal.pone.0005077. Epub 2009 Apr 4. PLoS One. 2009. PMID: 19347037 Free PMC article. - A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas.
Meehan R, Kummar S, Do K, O'Sullivan Coyne G, Juwara L, Zlott J, Rubinstein L, Doroshow JH, Chen AP. Meehan R, et al. Oncologist. 2018 Nov;23(11):1269-e125. doi: 10.1634/theoncologist.2018-0203. Epub 2018 May 31. Oncologist. 2018. PMID: 29853657 Free PMC article. Clinical Trial. - Progress toward overcoming hypoxia-induced resistance to solid tumor therapy.
Karakashev SV, Reginato MJ. Karakashev SV, et al. Cancer Manag Res. 2015 Aug 12;7:253-64. doi: 10.2147/CMAR.S58285. eCollection 2015. Cancer Manag Res. 2015. PMID: 26316817 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical